ID

22395

Beschrijving

European Compliance Study in Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00466739

Link

https://clinicaltrials.gov/show/NCT00466739

Trefwoorden

Versies (1)
  1. 01-06-17 01-06-17 -
Geüploaded op

1 juni 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Parkinson's Disease NCT00466739

Engels

Eligibility Parkinson's Disease NCT00466739

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
men or women between 18 and 80 years.
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
patient has idiopathic parkinson's disease according to brain bank criteria. -
Beschrijving

Parkinson Disease

Datatype

boolean

Alias
UMLS CUI [1]
C0030567
reference hughes a j, daniel s e, kilford l, lees a j, accuracy of clinical -
Beschrijving

Bibliographic Reference

Datatype

boolean

Alias
UMLS CUI [1]
C1514811
diagnosis of idiopathic parkinson's disease; a clinical pathological study of 100 cases, jnnp 1992, 55(3): 181 - 184
Beschrijving

Bibliographic Reference

Datatype

boolean

Alias
UMLS CUI [1]
C1514811
patient is on stable doses of anti-parkinson's disease medication, which are not expected to change during the study period.
Beschrijving

Antiparkinson Agents Dose Stable | Antiparkinson Agents unchanged

Datatype

boolean

Alias
UMLS CUI [1,1]
C0003405
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C0003405
UMLS CUI [2,2]
C0442739
patient is taking levodopa and/or dopamine agonist treatment.
Beschrijving

Levodopa | Dopamine Agonists

Datatype

boolean

Alias
UMLS CUI [1]
C0023570
UMLS CUI [2]
C0178601
patient (assisted by a carer where appropriate) is able to take their medication using the mems (electronic monitoring) containers.
Beschrijving

Pharmaceutical Preparations Intake Using Electronic monitor System

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1512806
UMLS CUI [1,3]
C1524063
UMLS CUI [1,4]
C0336646
UMLS CUI [1,5]
C0449913
patients using a dosette box or similar device for their medication are willing to use the mems containers for their pd medication
Beschrijving

Dosette Use of | Pharmaceutical Preparations Intake Using Electronic monitor System

Datatype

boolean

Alias
UMLS CUI [1,1]
C1553470
UMLS CUI [1,2]
C1524063
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1512806
UMLS CUI [2,3]
C1524063
UMLS CUI [2,4]
C0336646
UMLS CUI [2,5]
C0449913
the investigator judges that the patient's care and symptom control will not be adversely affected by entering the study and using the mems device.
Beschrijving

Patient care | Symptom control | Study Subject Participation Status | Pharmaceutical Preparations Intake Using Electronic monitor System

Datatype

boolean

Alias
UMLS CUI [1]
C0017313
UMLS CUI [2]
C1274136
UMLS CUI [3]
C2348568
UMLS CUI [4,1]
C0013227
UMLS CUI [4,2]
C1512806
UMLS CUI [4,3]
C1524063
UMLS CUI [4,4]
C0336646
UMLS CUI [4,5]
C0449913
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient is taking anti-parkinson's disease therapy intermittently or on "as required" basis (such as rescue therapy for off periods). intermittent domperidone is allowed.
Beschrijving

Therapeutic procedure Intermittent Parkinson Disease | Domperidone

Datatype

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0205267
UMLS CUI [1,3]
C0030567
UMLS CUI [2]
C0013015
severe co-morbid condition such as severe heart, liver, or kidney disease or cancer diagnosis where the co-morbid condition is of greater health significance than the parkinson's disease in terms of life expectancy and levels of care required.
Beschrijving

Comorbidity Severe | Heart Disease Severe | Liver disease Severe | Kidney Disease Severe | Malignant Neoplasms | Parkinson Disease | Life Expectancy | Level of Care Patient need for

Datatype

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C0018799
UMLS CUI [2,2]
C0205082
UMLS CUI [3,1]
C0023895
UMLS CUI [3,2]
C0205082
UMLS CUI [4,1]
C0022658
UMLS CUI [4,2]
C0205082
UMLS CUI [5]
C0006826
UMLS CUI [6]
C0030567
UMLS CUI [7]
C0023671
UMLS CUI [8,1]
C1547668
UMLS CUI [8,2]
C0686904
patient is expected to undergo hospital admission during the study period (such as elective surgery).
Beschrijving

Hospital admission Expected | Elective Surgical Procedures

Datatype

boolean

Alias
UMLS CUI [1,1]
C0184666
UMLS CUI [1,2]
C1517001
UMLS CUI [2]
C0206058
patient is on non standard drug treatment / combination therapy. this would include e.g. a combination of 2 different oral dopamine agonists, doses of dopamine agonist taken at higher than recommended for routine practice.
Beschrijving

Pharmacotherapy Investigational | Combined Modality Therapy | Dopamine Agonists Different Quantity | Dopamine Agonists High dose

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013216
UMLS CUI [1,2]
C1517586
UMLS CUI [2]
C0009429
UMLS CUI [3,1]
C0178601
UMLS CUI [3,2]
C1705242
UMLS CUI [3,3]
C1265611
UMLS CUI [4,1]
C0178601
UMLS CUI [4,2]
C0444956
new antiparkinson treatment is being introduced at the time of recruitment or during the one month monitoring period.
Beschrijving

Antiparkinson Agents new therapy

Datatype

boolean

Alias
UMLS CUI [1,1]
C0003405
UMLS CUI [1,2]
C3242274
patient is taking only adjunct therapy (eg. selegiline, amantadine, anticholinergic therapy).
Beschrijving

Adjuvant therapy | Selegiline | Amantadine | Anticholinergic Agents

Datatype

boolean

Alias
UMLS CUI [1]
C0677850
UMLS CUI [2]
C0036579
UMLS CUI [3]
C0002403
UMLS CUI [4]
C0242896
patient is taking part in a clinical trial.
Beschrijving

Study Subject Participation Status

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
Terug naar het begin van de pagina

Similar models

Eligibility Parkinson's Disease NCT00466739

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
men or women between 18 and 80 years.
boolean
C0001779 (UMLS CUI [1])
Parkinson Disease
Item
patient has idiopathic parkinson's disease according to brain bank criteria. -
boolean
C0030567 (UMLS CUI [1])
Bibliographic Reference
Item
reference hughes a j, daniel s e, kilford l, lees a j, accuracy of clinical -
boolean
C1514811 (UMLS CUI [1])
Bibliographic Reference
Item
diagnosis of idiopathic parkinson's disease; a clinical pathological study of 100 cases, jnnp 1992, 55(3): 181 - 184
boolean
C1514811 (UMLS CUI [1])
Antiparkinson Agents Dose Stable | Antiparkinson Agents unchanged
Item
patient is on stable doses of anti-parkinson's disease medication, which are not expected to change during the study period.
boolean
C0003405 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0003405 (UMLS CUI [2,1])
C0442739 (UMLS CUI [2,2])
Levodopa | Dopamine Agonists
Item
patient is taking levodopa and/or dopamine agonist treatment.
boolean
C0023570 (UMLS CUI [1])
C0178601 (UMLS CUI [2])
Pharmaceutical Preparations Intake Using Electronic monitor System
Item
patient (assisted by a carer where appropriate) is able to take their medication using the mems (electronic monitoring) containers.
boolean
C0013227 (UMLS CUI [1,1])
C1512806 (UMLS CUI [1,2])
C1524063 (UMLS CUI [1,3])
C0336646 (UMLS CUI [1,4])
C0449913 (UMLS CUI [1,5])
Dosette Use of | Pharmaceutical Preparations Intake Using Electronic monitor System
Item
patients using a dosette box or similar device for their medication are willing to use the mems containers for their pd medication
boolean
C1553470 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C1512806 (UMLS CUI [2,2])
C1524063 (UMLS CUI [2,3])
C0336646 (UMLS CUI [2,4])
C0449913 (UMLS CUI [2,5])
Patient care | Symptom control | Study Subject Participation Status | Pharmaceutical Preparations Intake Using Electronic monitor System
Item
the investigator judges that the patient's care and symptom control will not be adversely affected by entering the study and using the mems device.
boolean
C0017313 (UMLS CUI [1])
C1274136 (UMLS CUI [2])
C2348568 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C1512806 (UMLS CUI [4,2])
C1524063 (UMLS CUI [4,3])
C0336646 (UMLS CUI [4,4])
C0449913 (UMLS CUI [4,5])
Item Group
C0680251 (UMLS CUI)
Therapeutic procedure Intermittent Parkinson Disease | Domperidone
Item
patient is taking anti-parkinson's disease therapy intermittently or on "as required" basis (such as rescue therapy for off periods). intermittent domperidone is allowed.
boolean
C0087111 (UMLS CUI [1,1])
C0205267 (UMLS CUI [1,2])
C0030567 (UMLS CUI [1,3])
C0013015 (UMLS CUI [2])
Comorbidity Severe | Heart Disease Severe | Liver disease Severe | Kidney Disease Severe | Malignant Neoplasms | Parkinson Disease | Life Expectancy | Level of Care Patient need for
Item
severe co-morbid condition such as severe heart, liver, or kidney disease or cancer diagnosis where the co-morbid condition is of greater health significance than the parkinson's disease in terms of life expectancy and levels of care required.
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0018799 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0023895 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0022658 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0006826 (UMLS CUI [5])
C0030567 (UMLS CUI [6])
C0023671 (UMLS CUI [7])
C1547668 (UMLS CUI [8,1])
C0686904 (UMLS CUI [8,2])
Hospital admission Expected | Elective Surgical Procedures
Item
patient is expected to undergo hospital admission during the study period (such as elective surgery).
boolean
C0184666 (UMLS CUI [1,1])
C1517001 (UMLS CUI [1,2])
C0206058 (UMLS CUI [2])
Pharmacotherapy Investigational | Combined Modality Therapy | Dopamine Agonists Different Quantity | Dopamine Agonists High dose
Item
patient is on non standard drug treatment / combination therapy. this would include e.g. a combination of 2 different oral dopamine agonists, doses of dopamine agonist taken at higher than recommended for routine practice.
boolean
C0013216 (UMLS CUI [1,1])
C1517586 (UMLS CUI [1,2])
C0009429 (UMLS CUI [2])
C0178601 (UMLS CUI [3,1])
C1705242 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0178601 (UMLS CUI [4,1])
C0444956 (UMLS CUI [4,2])
Antiparkinson Agents new therapy
Item
new antiparkinson treatment is being introduced at the time of recruitment or during the one month monitoring period.
boolean
C0003405 (UMLS CUI [1,1])
C3242274 (UMLS CUI [1,2])
Adjuvant therapy | Selegiline | Amantadine | Anticholinergic Agents
Item
patient is taking only adjunct therapy (eg. selegiline, amantadine, anticholinergic therapy).
boolean
C0677850 (UMLS CUI [1])
C0036579 (UMLS CUI [2])
C0002403 (UMLS CUI [3])
C0242896 (UMLS CUI [4])
Study Subject Participation Status
Item
patient is taking part in a clinical trial.
boolean
C2348568 (UMLS CUI [1])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial